Mesenchymal Stem Cells in the Treatment of Burn Wounds (NCT07580755) | Clinical Trial Compass
RecruitingNot Applicable
Mesenchymal Stem Cells in the Treatment of Burn Wounds
China90 participantsStarted 2026-04-27
Plain-language summary
Burn patients were randomly divided into the low-dose stem cell gel group, the high-dose stem cell gel group, and the placebo group (with only the gel), and received the same treatment under the same conditions simultaneously.
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Voluntary participation and signing of the informed consent form;
. During this clinical study, single person, single donor skin area (lateral thigh or trunk) treatment;
. Skin burn area \< 30% of total body surface area (TBSA);
. The donor skin area is the first time for donation, and the donor skin area is medium-thick skin (thickness approximately 0.4mm);
. The area of the excised skin flap ≥ 90 cm2;
. Able to cooperate with this study protocol and accept regular postoperative follow-up visits.
Exclusion criteria
. Those allergic to sodium alginate (gel component);
. Electric shock injuries, chemical burns, radiation injuries or combined with other traumas;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Re-epithelialization areas
Timeframe: Up to 6 month
2
Complete burn wound healing
Timeframe: Up to 12 month
Trial details
NCT IDNCT07580755
SponsorThe First Affiliated Hospital of Xinxiang Medical College
. Subjects with severe systemic diseases (judged by the researchers);
. Subjects with uncontrolled hypertension or diabetes (judged by the researchers);
. Pregnant or lactating women;
. Subjects whose condition may affect the study assessment or require the concurrent use of medical treatments that may affect the efficacy assessment;
. Subjects with acute or chronic kidney diseases, renal failure or serum creatinine level = 1.5 times the upper limit of normal value;
. Subjects with acute or chronic liver diseases, total bilirubin, alanine aminotransferase, aspartate aminotransferase = 2.0 times the upper limit of normal value;